153Sm-Oxabiphor (153Sm-ETMP) is a therapeutic agent with a profile similar to 153Sm-Lexidronam and developed to by-pass patents or territory exclusivity. It is similarly used for the relief of bone pain in patients with multiple osteoblastic skeletal metastases which take up 99mTc-bisphophonate on bone scan. This drug is mainly available in former CIS countries and some Asian countries.
Target/Mechanism: Bones
Leading Emitter: beta electrons (β–)